SilenciX cell lines are target-specific silenced cells, produced as ready-to-use validated models, thus enabling researchers to focus on their experimental work without having to first construct the tools required for their studies. The innovative technology is based on non-viral transfections of non-integrative vectors. The episomal vectors are maintained tethered to the host chromosomes, at a very low copy number per cell.
Guarantee of target-specific knock-down at RNA level is at least 70%, cell lines produced so far mostly show over 85% silencing. Design of shRNAs is powered by the new DSIR algorithm for the prediction of RNAi efficacy and off-target blast screening.
The SilenciX technology allows long-term studies, consistent large cell supplies and high reproducibility in experiments, with no additional stress related to cell transfections, making it a reliable tool for target validation and drug discoveries in Life Sciences.
Dr Ali el Bayâ of tebu-bio (co-sponsors of the meeting) will be presenting SilenciX on Wednesday October 29th.
Further information and recent publications mentioning the SilenciX cell lines can be found at http://www.tebu-
